HomeCompareBAX vs AXON

BAX vs AXON: Dividend Comparison 2026

BAX yields 2.28% · AXON yields 0.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BAX wins by $284.00 in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
AXON
AXON
● Live price
0.48%
Share price
$415.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$49.72
Full AXON calculator →

Portfolio growth — BAX vs AXON

📍 BAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXAXON
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + AXON cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
AXON pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
AXON
Annual income on $10K today (after 15% tax)
$40.96/yr
After 10yr DRIP, annual income (after tax)
$42.26/yr
At 15% tax rate, AXON beats the other by $33.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + AXON for your $10,000?

BAX: 50%AXON: 50%
100% AXON50/50100% BAX
Portfolio after 10yr
$20.5K
Annual income
$29.99/yr
Blended yield
0.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AXON right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
AXON
Analyst Ratings
15
Buy
4
Hold
Consensus: Buy
Price Target
$750.00
+80.7% upside vs current
Range: $690.00 — $820.00
Altman Z
6.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
AXON buys
0
No recent congressional trades found for BAX or AXON in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXAXON
Forward yield2.28%0.48%
Annual dividend / share$0.36$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%0%
Portfolio after 10y$20.6K$20.3K
Annual income after 10y$10.26$49.72
Total dividends collected$602.00$490.00
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$19.75$750.00

Year-by-year: BAX vs AXON ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrAXON PortfolioAXON Income/yrGap
1← crossover$10,866$166.33$10,748$48.18+$118.00BAX
2$11,750$123.31$11,549$48.40+$201.00BAX
3$12,664$90.97$12,406$48.61+$258.00BAX
4$13,617$66.89$13,323$48.80+$294.00BAX
5$14,619$49.07$14,305$48.98+$314.00BAX
6$15,679$35.94$15,355$49.14+$324.00BAX
7$16,802$26.30$16,479$49.30+$323.00BAX
8$17,998$19.23$17,682$49.45+$316.00BAX
9$19,272$14.05$18,970$49.59+$302.00BAX
10$20,631$10.26$20,347$49.72+$284.00BAX

BAX vs AXON: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

AXONStock

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Full AXON Calculator →
📬

Get this BAX vs AXON comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.